Inspire Investing LLC Trims Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Inspire Investing LLC lessened its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 83.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,022 shares of the biotechnology company’s stock after selling 157,281 shares during the quarter. Inspire Investing LLC’s holdings in ADMA Biologics were worth $358,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its stake in shares of ADMA Biologics by 1.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock valued at $37,813,000 after acquiring an additional 35,707 shares during the last quarter. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ADMA Biologics during the 1st quarter worth about $17,221,000. Renaissance Technologies LLC grew its holdings in shares of ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after buying an additional 575,100 shares in the last quarter. Federated Hermes Inc. raised its position in shares of ADMA Biologics by 15.5% in the second quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock valued at $22,022,000 after buying an additional 263,677 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of ADMA Biologics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock valued at $7,398,000 after buying an additional 27,357 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ADMA shares. HC Wainwright lifted their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday. Finally, Mizuho increased their target price on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Up 1.2 %

Shares of NASDAQ ADMA opened at $19.98 on Friday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $4.63 billion, a PE ratio of -999.00 and a beta of 0.61. The firm has a fifty day moving average of $15.77 and a 200-day moving average of $10.96. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $20.16.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same period in the prior year, the firm posted ($0.02) earnings per share. The firm’s revenue was up 78.4% on a year-over-year basis. On average, analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at $7,589,587.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.